BioCentury | Oct 10, 2011
Finance

Venture's stress

...Meritage Pharma Inc. in June 2008; Prospect did not invest in Meritage's series A round Visiogen Inc....
BioCentury | Oct 26, 2009
Company News

Visiogen Inc., Abbott deal

...of ophthalmic medical device company Visiogen for $400 million in cash (see BioCentury, Sept. 7). Visiogen Inc....
BioCentury | Sep 7, 2009
Company News

Visiogen, Abbott deal

...Abbott will acquire ophthalmic medical device company Visiogen for $400 million in cash. Visiogen markets its...
...U.S. The deal is expected to close in 4Q09. J.P. Morgan Securities Inc. advised Visiogen. Visiogen Inc....
Items per page:
1 - 3 of 3
BioCentury | Oct 10, 2011
Finance

Venture's stress

...Meritage Pharma Inc. in June 2008; Prospect did not invest in Meritage's series A round Visiogen Inc....
BioCentury | Oct 26, 2009
Company News

Visiogen Inc., Abbott deal

...of ophthalmic medical device company Visiogen for $400 million in cash (see BioCentury, Sept. 7). Visiogen Inc....
BioCentury | Sep 7, 2009
Company News

Visiogen, Abbott deal

...Abbott will acquire ophthalmic medical device company Visiogen for $400 million in cash. Visiogen markets its...
...U.S. The deal is expected to close in 4Q09. J.P. Morgan Securities Inc. advised Visiogen. Visiogen Inc....
Items per page:
1 - 3 of 3